US Government As Represented by the Secretary of the Army

Charles H Hoke

Kenneth H Eckels

Doria R Dubois

Bruce L Innis

Joseph R Putnak

David Vaughn

Richard Lloyd Warren

J Robert Putnak

Wellington Sun

Niranjan Kanesa-Thasan

Hideo Sumiyoshi

Niranjan Kanessa-thasan

Niranian Kanesa-thasan

Sun Wellington

Erik A Henchai

Joseph B Putnak

Ashok Kumar Srivastava

The present invention provides vaccine compositions of attenuated dengue virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against all four dengue virus serotypes by administration of attenuated dengue-1, dengue-2, dengue-3, and dengue-4 virus.

Multivalent dengue virus vaccine

The present invention provides vaccine compositions of attenuated dengue-4 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-4 virus by administration of attenuated dengue-4 virus.

Attenuated dengue-4 virus vaccine

The present invention provides immunogenic compositions of attenuated dengue-1 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-1 virus by administration of attenuated dengue-1 virus.

Attenuated dengue-3 virus vaccine

The present invention provides vaccine compositions of attenuated dengue-2 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-2 virus by administration of attenuated dengue-2 virus.

Attenuated dengue-2 virus vaccine

A recombinant protein encompassing a C-terminal protion from the structural envelope glycoprotein and an N-terminal portion from non-structural protein one of dengue type 2 virus was expressed in Escherichia coli as a fusion protein with Staphylococcal protein A. The recombinant protein was found to provide protection against lethal challenge with dengue 2 in mice.

Recombinant vaccine made in E. coli against dengue virus

cDNA clones containing the entire genome of Japanese encephalitis virus (JEV) were used to produce infectious, recombinant JEV particles with diverse virulence properties. Certain viruses retained the immunogenicity of JEV, but lacked the ability to cause encephalitis. The mutation associated with this loss of neurovirulence was localized to a nucleotide substitution in the codon encoding the 138th amino acid of the envelop protein, resulting in a mutation of an acidic amino acid to a basic amino acid. Attenuated viruses containing this mutation form the basis of a greatly improved, molecularly defined vaccine for the prevention of Japanese encephalitis in humans.

Infectious Japanese encephalitis virus cDNA clones that produce highly

Growing community of inventors

Columbia, MD, United States of America

Charles H Hoke